AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma
Phase 3positiveEtentamigPositive
AI Analysis
Summary
AbbVie announced positive Phase 3 CERVINO trial results for Etentamig in relapsed/refractory multiple myeloma, demonstrating 74% objective response rate and 60% risk reduction in disease progression versus standard therapies.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Etentamig achieved 74% objective response rate and 60% risk reduction in disease progression or death versus standard therapies
Importance:8/10
Sentiment:
0.85
multiple myelomaoncologyPhase 3positive datarelapsed/refractory
Related Companies
Read the original article
Published by PR Newswire Biotech on September 3, 2026 1:15 PM